Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904) has a cash flow conversion efficiency ratio of 0.050x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($118.87 Million) by net assets ($2.36 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Shanghai Shenqi Pharmaceutical Investmen net asset quality index to measure how much of total assets are equity-financed.
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Shanghai Shenqi Pharmaceutical Investmen earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Enerside Energy S.A.
MC:ENRS
|
-2.096x |
|
SFD SA ZY -10
F:7PQ
|
0.072x |
|
A SPAC III Acquisition Corp. Class A Ordinary Shares
NASDAQ:ASPC
|
-0.056x |
|
Flagship Investments Ltd
AU:FSI
|
-0.006x |
|
Fusemachines Inc. Common stock
NASDAQ:FUSE
|
1.481x |
|
OD6 Metals Ltd
AU:OD6
|
-0.066x |
|
Ginegar
TA:GNGR
|
0.039x |
|
Cogra 48 Société Anonyme
PA:ALCOG
|
0.140x |
Annual Cash Flow Conversion Efficiency for Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (2015–2024)
The table below shows the annual cash flow conversion efficiency of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Shanghai Shenqi Pharmaceutical Investmen stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.43 Billion | $207.79 Million | 0.086x | -5.06% |
| 2023-12-31 | $2.39 Billion | $215.59 Million | 0.090x | -32.99% |
| 2022-12-31 | $2.37 Billion | $319.23 Million | 0.135x | +74.76% |
| 2021-12-31 | $2.39 Billion | $184.26 Million | 0.077x | +80.90% |
| 2020-12-31 | $2.33 Billion | $99.10 Million | 0.043x | -11.67% |
| 2019-12-31 | $2.66 Billion | $128.28 Million | 0.048x | -15.67% |
| 2018-12-31 | $2.60 Billion | $148.53 Million | 0.057x | +115.90% |
| 2017-12-31 | $2.53 Billion | $66.99 Million | 0.026x | +11200.02% |
| 2016-12-31 | $2.43 Billion | $570.41K | 0.000x | -98.22% |
| 2015-12-31 | $2.29 Billion | $30.12 Million | 0.013x | -- |
About Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., together with its subsidiaries, operates as a pharmaceutical manufacturing holding investment company in China. The company engages in the research and development, and production of anti-tumor, cardiovascular, cerebrovascular, rheumatism bone pain, tonic and sedative, cold and cough, anti-fungal, gynecology, and other treatment fiel… Read more